Company intelligence / Profile preview
MedRegen LLC
- Ownership
- Private
- Development stage
- Other
01
Overview
MedRegen has completed a Phase I first-in-human study showing MRG-001 is safe across all dose ranges. The intermediate dose group demonstrated significant white blood cell, stem cell, and immunoregulatory cell mobilization. The FDA has approved their IND to initiate a Phase IIa dose-ranging study for ARDS (NCT06308926). They have also completed a Phase II Wound Healing Study at Northwestern University.
- Therapeutic areas
- GastroenterologyPulmonologyDermatologyOtherInfectious Diseases
- Modalities
- Small moleculesfixed-dose drug combinations
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Premier CDMO (unnamed)
Beyond the preview
Go deeper on MedRegen LLC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MedRegen LLC.